Antibiotic heterogeneity optimizes antimicrobial prescription and enables resistant pathogen control in the intensive care unit

Surgical Infections

Volumn 13, Issue 4, 2012, Pages 194-202

  Piper, Greta L ^a   Kaplan, Lewis J ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BETA LACTAMASE INHIBITOR; CARBAPENEM; CEPHALOSPORIN; LINCOSAMIDE; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VANCOMYCIN;

ANTIBIOTIC HETEROGENEITY; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIUM ISOLATE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLOSTRIDIUM DIFFICILE INFECTION; CONFERENCE PAPER; DISEASE TRANSMISSION; GASTROINTESTINAL TRACT; GRAM NEGATIVE SEPSIS; HUMAN; INFECTION CONTROL; INTENSIVE CARE UNIT; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTIDRUG RESISTANCE; MULTIDRUG RESISTANT ORGANISM; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; SEPSIS; SURGICAL INFECTION;

ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; INFECTION CONTROL; INTENSIVE CARE UNITS;

EID: 84867023885     PISSN: 10962964     EISSN: 15578674     Source Type: Journal    
DOI: 10.1089/sur.2012.121     Document Type: Conference Paper

References (107)

1. Rogers BA, Aminzadeh Z, Hayashi Y, Paterson DL. Country-to-country transfer of patients and the risk of multi-resistant bacterial infection. Clin Infect Dis 2011;53: 49-56.
2. Barie PS. Multidrug-resistant organisms and antibiotic management. Surg Clin North Am 2012;92:345-391, ix-x.
3. Barie PS. Multiple organ dysfunction syndrome in critical surgical illness. Surg Infect 2009;10:369-377.
4. Barie PS, Hyoo LJ, Shou J, Eachempati SR. Decreasing magnitude of multiple organ dysfunction syndrome despite increasingly severe critical surgical illness: A 17-year longitudinal study. J Trauma 2008;65:1227-1235.
5. Donskey CJ. The role of the intestinal tract as a reservoir and source for transmission of nosocomial pathogens. Clin Infect Dis 2004;39:219-226. (Pubitemid 38971493)
6. Doyle JS, Buising KL, Thursky KA, et al. Epidemiology of infections acquired in intensive care units. Semin Respir Crit Care Med 2011;32:115-138.
7. Rosenberger LH, Riccio LM, Campbell KT, et al. Quarantine, isolation, and cohorting: From cholera to Klebsiella. Surg Infect 2012;13:69-73.
8. Cherry-Bukowiec JR, Denchen K, Dickinson S, et al. Prevention of catheter-related blood stream infection: Back to basics? Surg Infect 2011;12:27-32.
9. Sihler KC, Chenoweth C, Zalewski C, et al. Catheter-related vs. catheter-associated blood stream infections in the intensive care unit: Incidence, microbiology, and implications. Surg Infect 2010;11:529-534.
10. Gunst M, Matsushima K, Vanek S, et al. Peripherally inserted central catheters may lower the incidence of catheter-related blood stream infections in patients in surgical intensive care units. Surg Infect 2011;12:279-282.
11. O'Grady NP, Alexander M, Burns LA, et al. Guidelines for the prevention of intravascular catheter-related infections. Clin Infect Dis 2011;52:162-193.
12. Stuart JI, John MA, Milburn S, et al. Susceptibility patterns of coagulase-negative staphylococci to several newer antimicrobial agents in comparison with vancomycin and ox-acillin. Int J Antimicrob Agents 2011;37:248-252.
13. Clark C, McGhee P, Appelbaum PC, Kosowska-Shick K. Multistep resistance development studies of ceftaroline in gram-positive and-negative bacteria. Antimicrob Agents Chemother 2011;55:2344-2351.
14. Rice LB. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: No ESKAPE. J Infect Dis 2008;197:1079-1081. (Pubitemid 351590040)
15. Cocanour CS. Best strategies in recurrent or persistent Clostridium difficile colitis. Surg Infect 2011;12:235-239.
16. Harbrecht BG, Franklin GA, Shirley RM, et al. Statewide experience with Clostridium difficile colitis in academic and non-academic medical centers. Surg Infect 2012;13:88-92.
17. Olivas AD, Umanskiy K, Zuckerbraun B, Alverdy JC. Avoiding colectomy during surgical management of fulminant Clostridium difficile colitis. Surg Infect 2010;11:299-305.
18. Malkan AD, Pimiento JM, Maloney SP, et al. Unusual manifestations of Clostridium difficile infection. Surg Infect 2010;11:333-337.
19. Peterson LR. Bad bugs, no drugs: No ESCAPE revisited [correspondence]. Clin Infect Dis 2009;49:992-993.
20. Walk ST, Young VB. Emerging insights into antibiotic-associated diarrhea and Clostridium difficile infection through the lens of microbial ecology. Interdiscip Perspect Infect Dis 2008;125081.
21. Vollaard EJ, Clasener HA. Colonization resistance. Anti-microb Agents Chemother 1994;38:409-414. (Pubitemid 24072223)
22. Barlos D, Deitch EA, Watkins AC, et al. Trauma-hemorrhagic shock-induced pulmonary epithelial and endothelial cell injury utilizes different programmed cell death signaling pathways. Am J Physiol Lung Cell Mol Physiol 2009; 296:L404-L417.
23. Paul M, Silbiger I, Grozinsky S, et al. Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis. Cochrane Database Syst Rev 2006;CD003344.
24. Paul M, Benuri-Sailiger I, Soares-Weiser K, et al. Beta lac-tam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: Systematic review and meta-analysis of randomised trials. BMJ 2004;328:668.
25. Falagas ME, Matthaiou DK, Bliziotis IA. The role of ami-noglycosides in combination with a beta-lactam for the treatment of bacterial endocarditis: A meta-analysis of comparative trials. J Antimicrob Chemother 2006;57:639-647.
26. Paul M, Soares-Weiser K, Grozinsky S, Leibovici L. Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropaenia. Cochrane Database Syst Rev 2003;(3):CD003038.
27. Bliziotis IA, Samonis G, Vardakas KZ, et al. Effect of ami-noglycoside and beta-lactam combination therapy versus beta-lactam monotherapy on the emergence of antimicrobial resistance: A meta-analysis of randomized, controlled trials. Clin Infect Dis 2005;41:149-158. (Pubitemid 40962494)
28. Paul M, Leibovici L. Combination antimicrobial treatment versus monotherapy: The contribution of meta-analysis. Infect Dis Clin North Am 2009;23:277-293.
29. Colodner R, Rock W, Chazan B, et al. Risk factors for the development of extended-spectrum beta-lactamase-producing bacteria in nonhospitalized patients. Eur J Clin Microbiol Infect Dis 2004;23:163-167. (Pubitemid 38471420)
30. Rice LB, Willey SH, Papanicolaou GA, et al. Outbreak of ceftazidime resistance caused by extended-spectrum beta-lactamases at a Massachusetts chronic-care facility. Anti-microb Agents Chemother 1990;34:2193-2199. (Pubitemid 20373856)
31. Paterson DL, Ko WC, Von Gottberg A, et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: Implications for the clinical microbiology laboratory. J Clin Microbiol 2001;39:2206-2212. (Pubitemid 32531482)
32. Yu WL, Jones RN, Hollis RJ, et al. Molecular epidemiology of extended-spectrum beta-lactamase producing, fluor-oquinolone-resistant isolates of Klebsiella pneumoniae in Taiwan. J Clin Microbiol 2002;40:4666-4669. (Pubitemid 35434964)
33. Kang CI, Kim SH, Park WB, et al. Bloodstream infections caused by Enterobacter species: Predictors of 30-day mortality rate and impact of broad-spectrum cephalosporin resistance on outcome. Clin Infect Dis 2004;39:812-818.
34. Muller A, Lopez-Lazano JM, Bertrand X, Talon D. Relationship between ceftriaxone use and resistance to third-generation cephalosporins among clinical strains of En-terobacter cloacae. J Antimicrob Chemother 2004;54:173-177. (Pubitemid 39028986)
35. Lee SO, Kim NJ, Choi SH, et al. Risk factors for acquisition of imipenem-resistant Acinetobacter baumannii: A case-control study. Antimicrob Agents Chemother 2004;48: 224-228. (Pubitemid 38040201)
36. Landman D, Quale JM, Mayorga D, et al. Citywide clonal outbreak of multiresistant Acinetobacter baumannii and Pseudomonas aeruginosa in Brooklyn, NY: The preantibiotic era has returned. Arch Intern Med 2002;162:1515-1520. (Pubitemid 34747486)
37. Manikal VM, Landman D, Saurina G, et al. Endemic car-bapenem-resistant Acinetobacter species in Brooklyn, New York: Citywide prevalence, interinstitutional spread, and relation to antibiotic usage. Clin Infect Dis 2000;31:101-106. (Pubitemid 32268946)
38. Cao B, Wang H, Sun H, et al. Risk factors and clinical outcomes of nosocomial multi-drug resistant Pesudomonas aeruginosa infections. J Hosp Infect 2004;57:112-118. (Pubitemid 38745423)
39. Carmeli Y, Troillet N, Eliopoulos GM, Samore MH. Emergence of antibiotic-resistant Pseudomonas aeruginosa: Comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother 1999;43:1379-1382. (Pubitemid 29259329)
40. Hsu DI, Okamoto MP, Murthy R, Wong-Beringer A. Fluoroquinolone-resistant Pseudomonas aeruginosa: Risk factors for acquisition and impact on outcomes. J Anti-microb Chemother 2005;55:535-541. (Pubitemid 40542596)
41. Zervos MJ, Hershberger E, Nicolau DP, et al. Relationship between fluoroquinolone use and changes in susceptibility to fluoroquinolones of selected pathogens in 10 United States teaching hospitals, 1991-2000. Clin Infect Dis 2003;37:1643-1648. (Pubitemid 37549951)
42. Khan R, Cheesbrough J. Impact of changes in antibiotic policy on Clostridium difficile-associated diarrhoea (CDAD) over a five-year period in a district general hospital. J Hosp Infect 2003;54:104-108. (Pubitemid 38002006)
43. Pepin J, Saheb N, Coulombe MA, et al. Emergence of fluoroquinolones as the predominant risk factor for Clos-tridium difficile-associated diarrhea: A cohort study during an epidemic in Quebec. Clin Infect Dis 2005;41:1254-1260. (Pubitemid 41532667)
44. Yip C, Loeb M, Salama S, et al. Quinolone use as a risk factor for nosocomial Clostridium difficile-associated diarrhea. Infect Control Hosp Epidemiol 2001;22:572-575. (Pubitemid 33104885)
45. Zhou Q, Moore C, Eden S, et al. Factors associated with acquisition of vancomycin-resistant enterococci (VRE) in roommate contacts of patients colonized or infected with VRE in a tertiary care hospital. Infect Control Hosp Epidemiol 2008;29:399-403.
46. Hong T, Moland ES, Abdalhamid B, et al. Escherichia coli: Development of carbapenem resistance during therapy. Clin Infect Dis 2005;40:e84-e86.
47. Kritsotakis EI, Tsioutis C, Roumbelaki M, et al. Antibiotic use and the risk of carbapenem-resistant extended-spectrum-b-lactamase-producing Klebsiella pneumoniae infection in hospitalized patients: Report of a double case-control study. J Antimicrob Chemother 2011;66:1383-1391.
48. Ho VP, Jenkins SG, Afaneh CI, et al. Use of meropenem by continuous infusion to treat a patient with a BLA(Kpc-2)-positive Klebsiella pneumoniae blood stream infection. Surg Infect 2011;12:325-327.
49. www.cdc.gov/abcs/reports-findings/mrsa.05.pdf; accessed October 26, 2011.
50. www.cdc.gov/abcs/reports-findings/mrsa.06.pdf; accessed October 26, 2011.
51. www.cdc.gov/abcs/reports-findings/mrsa.07.pdf; accessed October 26, 2011.
52. www.cdc.gov/abcs/reports-findings/mrsa.08.pdf; accessed October 26, 2011.
53. Ramsey AM, Zilberberg MD. Secular trends of hospitali-zation with vancomycin-resistant Enterococcus infection in the United States, 2000-2006. Infect Control Hosp Epidemiol 2009;30:184-186.
54. McDonald LC, Owings M, Jernigan DB. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg Infect Dis 2006;12:409-415.
55. Muto CA, Pokrywka M, Shutt K, et al. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol 2005;26:273-280. (Pubitemid 40445086)
56. Hidron AI, Edwards JR, Patel J, et al. NHSN annual update: Antimicrobial-resistant pathogens associated with healthcare-associated infections: Annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol 2008;29:996-1011.
57. Kallen AJ, Hidron AI, Patel J, Srinivasan A. Multidrug resistance among gram-negative pathogens that caused healthcare-associated infections reported to the National Healthcare Safety Network, 2006-2008. Infect Control Hosp Epidemiol 2010;31:528-531.
58. Brink AJ, Botha RF, Poswa X, et al. Antimicrobial susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in South African hospitals (SMART Study 2004-2009): Impact of the new carbapenem breakpoints. Surg Infect 2012;13:43-49.
59. Hawser SP, Bouchillon SK, Huban DJ, Badal RE. Epide-miologic trends, occurrence of extended-spectrum beta-lactamase production, and performance of ertapenem and comparators in patients with intra-abdominal infections: Analysis of global trend data from 2002-2007 from the SMART study. Surg Infect 2010;11:371-378.
60. Bradley SJ, Wilson AL, Allen MC, et al. The control of hyperendemic glycopeptide-resistant Enterococcus spp. on a haematology unit by changing antibiotic usage. J Anti-microb Chemother 1999;43:261-266. (Pubitemid 29082451)
61. Carmeli Y, Eliopoulos GM, Samore MH. Antecedent treatment with different antibiotic agents as a risk factor for vancomycin-resistant Enterococcus. Emerg Infect Dis 2002;8:802-807.
62. Landman D, Chockalingam M, Quale JM. Reduction in the incidence of methicillin-resistant Staphylococcus aureus and ceftazidime-resistant Klebsiella pneumoniae following changes in a hospital antibiotic formulary. Clin Infect Dis 1999;28:1062-1066. (Pubitemid 29203539)
63. Monnet DL, MacKenzie FM, Lopez-Lozano JM, et al. Antimicrobial drug use and methicillin-resistant Staphylococcus aureus, Aberdeen, 1996-2000. Emerg Infect Dis 2004;10: 1432-1441. (Pubitemid 39014157)
64. Madaras-Kelly KJ, Remington RE, Lewis PG, Stevens DL. Evaluation of an intervention designed to decrease the rate of nosocomial methicillin-resistant Staphylococcus aureus infection by encouraging decreased fluoroquinolone use. Infect Control Hosp Epidemiol 2006;27:155-169. (Pubitemid 43384762)
65. Weber SG, Gold HS, Hooper DC, et al. Fluoroquinolones and the risk for methicillin-resistant Staphylococcus aureus in hospitalized patients. Emerg Infect Dis 2003;9:1415-1422. (Pubitemid 37356215)
66. Dziekan G, Hahn A, Thune K, et al. Methicillin-resistant Staphylococcus aureus in a teaching hospital: Investigation of nosocomial transmission using a matched case-control study. J Hosp Infect 2000;46:263-270. (Pubitemid 32059793)
67. Schentag JJ, Hyatt JM, Carr JR, et al. Genesis of methicillin-resistant Staphylococcus aureus (MRSA), how treatment of MRSA infections has selected for vancomycin-resistant Enterococcus faecium, and the importance of antibiotic management and infection control. Clin Infect Dis 1998; 26:1204-1214.
68. Amin PB, Magnotti LJ, Fisher PE, et al. Prophylactic antibiotic days as a predictor of sensitivity patterns in Acine-tobacter pneumonia. Surg Infect 2011;12:33-38.
69. Burgess DS, Rapp RP. Bugs versus drugs: Addressing the pharmacist's challenge. Am J Health Syst Pharm 2008;65(9 Suppl 2):S4-S15. (Pubitemid 351668758)
70. Yong D, Toleman MA, Giske CG, et al. Characterization of a new metallo-beta-lactamase gene bla(ND-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob Agents Chemother 2009;53:5046-5054.
71. Pitout JD. Infections with extended-spectrum beta-lactamase-producing Enterobacteriaceae: Changing epidemiology and drug treatment choices. Drugs 2010;70:313-333.
72. Schwaber MJ, Carmeli Y. Carbapenem-resistant Entero-bacteriaceae: A potential threat. JAMA 2008;300:2911-2913.
73. Watanabe M, Iyobe S, Inoue M, Mitsuhashi S. Transferable imipenem resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1991;35:147-151.
74. Queenan AM, Bush K. Carbapenemases: The versatile beta-lactamases. Clin Microbiol Rev 2007;20:440-458.
75. Hill MJ, Drasar BS. The normal colonic bacterial flora. Gut 1975;16:318-323.
76. Tenover FC, Kalsi RK, Williams PP, et al. Carbapenem resistance in Klebsiella pneumoniae not detected by automated susceptibility testing. Emerg Infect Dis 2006;12: 1209-1213.
77. Gatt M, Reddy BS, MacFie J. Review article: Bacterial translocation in the critically ill: Evidence and methods of prevention. Aliment Pharmacol Ther 2007;25:741-557.
78. Silvestri L, Petrus AJ, Roos D, et al. Selective digestive decontamination, selective oropharyngeal decontamination, and oropharygeal chlorhexidine: Three different maneuvers. Surg Infect 2012;13:175-176.
79. Reed RL. Prevention of hospital-acquired infections by selective digestive decontamination. Surg Infect 2011;12: 221-229.
80. Kitchel B, Rasheed JK, Patel JB, et al. Molecular epidemiology of KPC-producing Klebsiella pneumoniae isolates in the United States: Clonal expansion of multilocus sequence type 258. Antimicrob Agents Chemother 2009;53:3365-3370.
81. Rolain JM, Parola P, Cornaglia G. New Delhi metallo-beta-lactamase (NDM-1): Towards a new pandemia? Clin Microbiol Infect 2010;16:1699-1701.
82. Stover CK, Pham XQ, Erwin AL, et al. Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen. Nature 2000;406:959-964.
83. Mesaros N, Nordmann P, Plesiat P, et al. Pseudomonas aer-uginosa: Resistance and therapeutic options at the turn of the new millennium. Clin Microbiol Infect 2007;13:560-578. (Pubitemid 46730662)
84. Fournier PE, Richet H. The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin Infect Dis 2006;42:692-699. (Pubitemid 43271386)
85. Maragakis LL, Perl TM. Acinetobacter baumannii: Epidemiology, antimicrobial resistance, and treatment options. Clin Infect Dis 2008;46:1254-1263. (Pubitemid 351589912)
86. Young LS, Sabel AL, Price CS. Epidemiologic, clinical and economic evaluation of an outbreak of clonal multidrug-resistant Acinetobacter baumannii infection in a surgical intensive care unit. Infect Control Hosp Epidemiol 2007;28: 1247-1254. (Pubitemid 47596563)
87. Lawrence KL, Kollef MH. Antimicrobial stewardship in the intensive care unit: Advances and obstacles. Am J Respir Crit Care Med 2009;179:434-438.
88. Deresinski S. Principles of antibiotic therapy in severe infections: Optimizing the therapeutic approach by use of laboratory and clinical data. Clin Infect Dis 2007;45(Suppl 3): S177-S183. (Pubitemid 47378904)
89. Adnan S, Paterson DL, Lipman J, et al. Pharmacokinetics of beta-lactam antibiotics in patients with intra-abdominal disease: A structured review. Surg Infect 2012;13:9-17.
90. Ho VP, Nocolav DP, Dakin GF, et al. Cefazolin dosing for surgical prophylaxis in morbidly obese patients. Surg Infect 2012;13:33-37.
91. Hibbard ML, Kopelman TR, O'Neill PJ, et al. Empiric broad-spectrum antibiotic therapy with an aggressive de-escalation strategy does not induce gram-negative pathogen resistance in ventilator-associated pneumonia. Surg Infect 2010;11:427-432.
92. Echempati SR, Huou LJ, Shou J, Barie PS. The pathogen of ventilator-associated pneumonia does not influence the mortality rate of surgical intensive care unit patients treated with a rotational antibiotic system. Surg Infect 2010;11:13-20.
93. Swanson JM, Wood GC, Croce MA, et al. Utility of preliminary bronchoalveolar lavage results in suspected ventilator-associated pneumonia. J Trauma 2008;65:1271-1277.
94. Sakamoto F, Yamada H, Suzuki C, et al. Increased use of alcohol-based hand sanitizers and successful eradication of methicillin-resistant Staphylococcus aureus from a neonatal intensive care unit: A multivariate time series analysis. Am J Infect Control 2010;38:529-534.
95. Durtch MJ, Fleming SB, Kauffmann RM, et al. Infection reduction strategies including antibiotic stewardship protocols in surgical and trauma intensive care units are associated with reduced resistant gram-negative healthcare-associated infections. Surg Infect 2011;12:15-25.
96. Zillich AJ, Sutherland JM, Wilson SJ, et al. Antimicrobial use control measures to prevent and control antimicrobial resistance in US hospitals. Infect Control Hosp Epidemiol 2006;27:1088-1095. (Pubitemid 44670986)
97. Recommendations for preventing the spread of vancomy-cin resistance: Recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm Rep 1995;44(RR-12):1-13.
98. Smith RL, Evans HL, Chong TW, et al. Reduction in rates of methicillin-resistant Staphylococcus aureus infection after introduction of quarterly linezolid-vancomycin cycling in a surgical intensive care unit. Surg Infect 2008;9:423-431.
99. Sandiumenge A, Diaz E, Rodriguez A, et al. Impact of diversity of antibiotic use on the development of antimicrobial resistance. J Antimicrob Chemother 2006;57:1197-1204. (Pubitemid 44644425)
100. Takesue Y, Nakajima K, Ichiki K, et al. Impact of a hospital-wide programme of heterogeneous antibiotic use on the development of antibiotic-resistant gram-negative bacteria. J Hosp Infect 2010;75:28-32.
101. Pestana D, Espinosa E, Sanguesa-Molina JR, et al. Compliance with a sepsis bundle and its effect on intensive care unit mortality in surgical septic shock patients. J Trauma 2010;69:1282-1287.
102. Dubose J, Teixeira PG, Inaba K, et al. Measurable outcomes of quality improvement using a daily quality rounds checklist: One-year analysis in a trauma intensive care unit with sustained ventilator-associated pneumonia reduction. J Trauma 2010;69:855-860.
103. Peterson LR. Currently available antimicrobial agents and their potential for use as monotherapy. Clin Microbiol Infect 2008;14(Suppl 6):S30-S45.
104. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society of Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010;31: 431-455.
105. Dryden M, Hand K, Davey P; BASC Council. Antibiotics for community-acquired pneumonia. J Antimicrob Che-mother 2009;64:1123-1125.
106. Pulcini C, Defres S, Aggarwal I, et al. Design of a "day 3 bundle" to improve the reassessment of inpatient empirical antibiotic prescriptions. J Antimicrob Chemother 2008;61: 1384-1388. (Pubitemid 351753611)
107. Dellit TH, Owens RC, McGowan JE Jr, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007;44:159-177. (Pubitemid 46084814)